About

Founded in 2021, TerThera strives to meet the growing global demand for radionuclides in cancer healthcare by providing a highly sustainable and uninterrupted supply of Terbium-161 for use in radioligand therapy. 

The scarcity of radionuclides for use in radioligand therapy impacts the lives of many cancer patients, with a secured stock of highly enriched gadolinium-160 our team promises to deliver therapeutic quantities of GMP-grade Terbium-161, expanding the options available for patient treatments. 

Having resolved the scarcity of Terbium-161, we aim to enable Terbium-161 radioligand therapy by supporting academic partners, preclinical, and clinical research towards patient treatment, ultimately working towards understanding the underlying mechanisms of internal radiation therapy. 

Contact us for further information regarding availability, collaborations, and new developments.